This stock’s been on a downtrend lately, with both the 9 and 21-day EMAs sloping downward—classic bearish momentum. 📉 The RSI hovering around 39 suggests it’s nearing oversold territory, but not quite there yet. Volume spiked on the big drop days (like April 10), signaling strong selling pressure. No clear reversal patterns yet, but if the RSI dips below 30 and volume slows, a bounce might be coming. For now? Hold or wait for confirmation—no rush to buy into this slide. 🚦

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG NOVN.SW: 90.63 CHF

Bearish views